Relmada Therapeutics Inc (RLMD)
3.66
-0.06
(-1.61%)
USD |
NASDAQ |
May 03, 16:00
3.66
0.00 (0.00%)
After-Hours: 16:09
Relmada Therapeutics Cash from Financing (Quarterly): -0.0985M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0985M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.4099M |
| September 30, 2022 | 0.5691M |
| June 30, 2022 | 14.09M |
| March 31, 2022 | 29.95M |
| December 31, 2021 | 161.84M |
| September 30, 2021 | 0.1852M |
| June 30, 2021 | 23.99M |
| March 31, 2021 | 1.928M |
| December 31, 2020 | 0.9442M |
| September 30, 2020 | 1.634M |
| June 30, 2020 | 22.89M |
| March 31, 2020 | 3.005M |
| September 30, 2019 | 1.168M |
| June 30, 2019 | 10.83M |
| March 31, 2019 | 1.639M |
| December 31, 2018 | 4.687M |
| September 30, 2018 | 0.3195M |
| June 30, 2018 | 0.2573M |
| Date | Value |
|---|---|
| March 31, 2018 | -0.0567M |
| December 31, 2017 | 2.387M |
| September 30, 2017 | 3.956M |
| June 30, 2017 | -0.0276M |
| March 31, 2017 | -0.0824M |
| December 31, 2016 | -0.0544M |
| September 30, 2016 | -0.1092M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | -0.0885M |
| December 31, 2015 | -0.0879M |
| September 30, 2015 | -0.0873M |
| June 30, 2015 | 0.0063M |
| March 31, 2015 | -0.0281M |
| December 31, 2014 | 9.018M |
| September 30, 2014 | 4.159M |
| February 28, 2014 | 0.00 |
| November 30, 2013 | 0.00 |
| August 31, 2013 | 0.02M |
| May 31, 2013 | 0.00 |
| February 28, 2013 | 0.00 |
| November 30, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0985M
Minimum
Dec 2023
161.84M
Maximum
Dec 2021
15.19M
Average
1.401M
Median
Cash from Financing (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 0.999M |
| Lifecore Biomedical Inc | 40.93M |
| Corvus Pharmaceuticals Inc | 0.00 |
| NeuroBo Pharmaceuticals Inc | 0.00 |
| Ensysce Biosciences Inc | 1.461M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.25M |
| Cash from Investing (Quarterly) | 7.741M |
| Free Cash Flow | -51.66M |
| Free Cash Flow Per Share (Quarterly) | -0.3405 |
| Free Cash Flow Yield | -46.89% |